Mirum Pharmaceuticals is a biopharmaceutical company focused on the identification, acquisition, development and commercialization of therapies for rare and orphan diseases. Co.'s focus is the development and commercialization of LIVMARLI® (maralixibat) oral solution (Livmarli) and volixibat. Livmarli is an oral solution approved as a once daily medicine for cholestatic pruritus in patients with Alagille syndrome one year of age and older. Co.'s second product candidate, volixibat, an oral, minimally-absorbed agent designed to inhibit ileal bile acid transporter, for the treatment of adult patients with cholestatic liver diseases. The MIRM YTD return is shown above.
The YTD Return on the MIRM YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether MIRM YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MIRM YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|